Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
European Journal of Neurology · 2024-08 · 31 (8)
DOI: 10.1111/ene.16331 ↗At a glance
Multizentrische Studie in European Journal of Neurology, published online on 2024-05-25. Written by Susanna Hallberg and 11 co-authors. Institution: Department of Clinical Sciences, Karolinska Institutet, Danderyds Sjukhus, Stockholm, Sweden. Major MEDLINE topics: Agammaglobulinemia, Rituximab, Immunologic Factors, Multiple Sclerosis. Cited 15 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY 4.0). Funded by: Neuroförbundet, Stockholm läns landsting.
Abstract (original language)
Background and purpose Mechanisms behind hypogammaglobulinaemia during rituximab treatment are poorly understood.
Methods
In this register‐based multi‐centre retrospective cohort study of multiple sclerosis (MS) patients in Sweden, 2745 patients from six participating Swedish MS centres were identified via the Swedish MS registry and included between 14 March 2008 and 25 January 2021. The exposure was treatment with at least one dose of rituximab for MS or clinically isolated syndrome, including data on treatment duration and doses. The degree of yearly decrease in immunoglobulin G (IgG) and immunoglobulin M (IgM) levels was evaluated.
Results
The mean decrease in IgG was 0.27 (95% confidence interval 0.17–0.36) g/L per year on rituximab treatment, slightly less in older patients, and without significant difference between sexes. IgG or IgM below the lower limit of normal (
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical Sciences, Karolinska Institutet, Danderyds Sjukhus, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
- Department of Clinical Sciences, Neurosciences, Unit of Neurology, Östersund, Umeå University, Umeå, Sweden.
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
ORCID profiles: Susanna Hallberg, Björn Evertsson, Malin Boremalm, Jonatan Salzer, Jan Lycke, Katharina Fink, Thomas Frisell, Anders Svenningsson
Funding
- Neuroförbundet
- Stockholm läns landsting
Cite
APA
Hallberg, S., Evertsson, B., Lillvall, E., Boremalm, M., de Flon, P., Wang, Y., Salzer, J., Lycke, J., Fink, K., Frisell, T., Al Nimer, F., & Svenningsson, A. (2024). Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European Journal of Neurology, 31(8). https://doi.org/10.1111/ene.16331
Vancouver
Hallberg S, Evertsson B, Lillvall E, Boremalm M, de Flon P, Wang Y, et al. Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European Journal of Neurology. 2024;31(8). doi:10.1111/ene.16331
BibTeX
@article{Hallberg2024,
author = {Hallberg, Susanna and Evertsson, Björn and Lillvall, Ellen and Boremalm, Malin and de Flon, Pierre and Wang, Yunzhang and Salzer, Jonatan and Lycke, Jan and Fink, Katharina and Frisell, Thomas and Al Nimer, Faiez and Svenningsson, Anders},
title = {Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {8},
doi = {10.1111/ene.16331}
}
EUVIMED